Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

BACKGROUND: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce glucose levels, body weight, and blood pressure, possibly resulting in cardiovascular protection. In phase III trials, SGLT2i were shown to increase HDL cholesterol. We aimed to evaluate whether the SGLT2i dapagliflozin affects H...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Fadini, Gian Paolo, Bonora, Benedetta Maria, Zatti, Giancarlo, Vitturi, Nicola, Iori, Elisabetta, Marescotti, Maria Cristina, Albiero, Mattia, Avogaro, Angelo
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5379610/
https://ncbi.nlm.nih.gov/pubmed/28376855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0529-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados